Cefpirome: Difference between revisions
Gerald Chi (talk | contribs) |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Cefpirome}} | |||
{{CMG}} | {{CMG}} | ||
Revision as of 14:53, 2 January 2014
| Cefpirome |
|---|
| CEFROM® Package Insert |
| Composition |
| Properties |
| Indications |
| Microbiology |
| Contraindications |
| Warnings and Precautions |
| Adverse Reactions |
| Drug Interactions |
| Dosage and Administration |
| How Supplied |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Cefpirome is a fourth-generation cephalosporin which is considered highly active against Gram-positive bacteria and Gram-negative bacteria including Pseudomonas aeruginosa. It is marketed under the brand name of CEFROM by Sanofi Aventis group India.
Category
Cephalosporin, Fourth-Generation
Mechanism of Action
Cefpirome blocks bacterial cell wall synthesis by binding to penicillin binding proteins. Cefpirome (not available in the United States) and cefepime are fourth-generation cephalosporins which possess antibacterial activity against several fastidious Gram negative bacteria.
Spectrum of Bacterial Susceptibility and Resistance
Currently, Bacteroides fragilis, Enterococci, Pseudomonas spp. and Staphylococci are resistant to Cefpirome Sulfate, and some Haemophilus spp. and Pneumococci have developed resistance to Cefpirome Sulfate to varying degrees.[1]